118 results
Page 6 of 6
424B2
lq4bw876e2 0md
6 May 19
Prospectus for primary offering
6:04am
6-K
EX-99.1
1mouqjjb
3 May 19
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
12:00am
424B5
8yuo5nskjvupbpr2
1 May 19
Prospectus supplement for primary offering
5:26pm
6-K
EX-99.1
twpsiylgd3jaa 2ab
1 May 19
Current report (foreign)
4:06pm
F-3ASR
0s8t7oe
29 Mar 19
Automatic shelf registration (foreign)
5:13pm
6-K
EX-99.1
rynl5zj k03w
7 Mar 19
Zai Lab Announces Financial Results and Corporate Update for Full Year 2018
7:36am
6-K
EX-99.1
4m4x6q7r
12 Dec 18
Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA
7:35am
6-K
EX-99.1
px9gnb18 pq
30 Nov 18
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development
6:06am
6-K
EX-99.1
94ezko9daei2hoj
22 Oct 18
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
7:48am
424B4
2kzc9zk8 efhq
7 Sep 18
Prospectus supplement with pricing info
12:00am
6-K
EX-99.1
6i6c0om 5dam4b93
14 Aug 18
Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors
7:36am
6-K
EX-99.1
x2vtgiyyd0y7rt
5 Jun 18
Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer
12:00am
6-K
EX-99.1
ljl7zpbt
2 May 18
Zai Lab Reports Full Year 2017 Financial Results and Corporate Update
7:14am
20-F
6nopabp7
30 Apr 18
Annual report (foreign)
9:07am
20-F
EX-4.11
9apll1flcr
30 Apr 18
Annual report (foreign)
9:07am
6-K
EX-99.1
f3szu k5zkb0grolb
25 Apr 18
Global Strategic Development Collaboration for ETX2514
12:00am